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OBJECTIVES The aim of this study was to determine the protective effect of carvedilol in anthracycline
(ANT)-induced cardiomyopathy (CMP).
BACKGROUND Despite its broad effectiveness, ANT therapy is associated with ANT-induced CMP. Recent
animal studies and experimental observations showed that carvedilol prevented development
of CMP due to chemotherapeutics. However, there is no placebo-controlled clinical trial
concerning prophylactic carvedilol use in preventing ANT-induced CMP.
METHODS Patients in whom ANT therapy was planned were randomized to administration of carvedilol
or placebo. We enrolled 25 patients in carvedilol and control groups. In the carvedilol group,
12.5 mg once-daily oral carvedilol was given during 6 months. The patients were evaluated
with echocardiography before and after chemotherapy. Left ventricular ejection fraction (EF)
and systolic and diastolic diameters were calculated.
RESULTS At the end of 6 months of follow-up, 1 patient in the carvedilol group and 4 in the control
group had died. Control EF was below 50% in 1 patient in the carvedilol group and in 5 in
the control group. The mean EF of the carvedilol group was similar at baseline and control
echocardiography (70.5 vs. 69.7, respectively; p 0.3), but in the control group the mean EF
at control echocardiography was significantly lower (68.9 vs. 52.3; p  0.001). Both systolic
and diastolic diameters were significantly increased compared with basal measures in the
control group. In Doppler study, whereas E velocities in the carvedilol group decreased, E
velocities and E/A ratios were significantly reduced in the control group.
CONCLUSIONS Prophylactic use of carvedilol in patients receiving ANT may protect both systolic and
diastolic functions of the left ventricle. (J Am Coll Cardiol 2006;48:2258–62) © 2006 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.052the American College of Cardiology Foundation
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cnthracycline (ANT) antibiotics are potent antineoplastic
gents. Unfortunately, despite its broad effectiveness, ANT
herapy is associated with irreversible dilated cardiomyopa-
hy (CMP). Toxic effect may occur at any stage of ANT
reatment. When it takes place, medical therapy is mostly
nsufficient. Therefore, prevention of CMP has great clini-
al importance.
There are several hypotheses to explain the mechanism of
NT-induced cardiotoxicity, including free oxygen radicals
1), apoptosis (2), mitochondrial dysfunction (1,3), and
ctivation of matrix metalloproteinase (4). Free radical
ormation is generally accepted as the main mechanism.
ardiomyocytes have poor antioxidant defense systems, and
ree oxygen radicals can damage various targets in the cell
5). This may result in impairment of cardiac contractility
nd the development of CMP.
Many different chemical agents have been examined to
revent ANT-induced CMP (6–8), and some of them
howed promising results. Carvedilol blocks beta1-, beta2-,
nd 1-adrenoceptors and has potent antioxidant and anti-
poptotic properties (9,10). Recent animal studies and
xperimental observations showed that carvedilol prevented
he development of CMP, free radical release, and apoptosis
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ccepted July 10, 2006.n cardiomyocytes due to chemotherapeutics (11–13).
arvedilol is already indicated in treatment of ANT-
nduced CMP to cease further deterioration in left ventric-
lar (LV) function and to improve symptoms (14). How-
ver, there is no placebo-controlled clinical trial concerning
rophylactic carvedilol use in preventing ANT-induced
MP. Therefore, we designed this study to establish the
rotective effect of carvedilol.
ETHODS
tudy population. Patients diagnosed with malignancy
nd planned ANT therapy (adriamycin or epirubicin) in the
ncology department of the Erciyes University Medical
chool between September 2003 and October 2004 were
nrolled. The patients were randomized to carvedilol or
ontrol groups. The exclusion criteria were earlier chemo-
herapy (CT) or radiotherapy, presence of congestive heart
ailure symptoms or established dilated or restrictive CMP,
oronary arterial disease history, presence of moderate or
evere mitral or aortic valve disease in baseline echocardio-
raph, any contraindication to carvedilol, bundle branch
lock, thyroid function disorder, or another comorbid dis-
ase. No patients were taking any of the drugs that affect
ardiac function, such as angiotensin-converting enzyme
nhibitors, angiotensin receptor blockers, diuretics, or beta-
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ommittee. All patients gave informed consent.
tudy design. This study was a randomized, single-blind,
nd placebo-controlled trial. In the carvedilol group,
2.5 mg once-daily oral carvedilol (Dilatrend; Roche SpA,
egrate MI, Italy) was started before CT and maintained for
months during CT. All patients received CT at a mean of
very 3 weeks. The primary end point in this study was
ystolic functions.
chocardiography. The patients were evaluated with
chocardiography before and after CT with Vingmed Sys-
em V (General Electric Medical System). Left ventricular
ystolic and diastolic diameters and ejection fraction (EF)
ere calculated (15). In transmitral pulsed Doppler exami-
ation, the peak velocities of early (E) and late diastolic flow
A), the E/A ratio, isovolumic relaxation time, and isov-
lemic contraction time were measured as previously de-
cribed (16). All echocardiograms were interpreted by 2
ardiologists who had no knowledge of the patient’s treat-
ent. Systolic dysfunction was defined by EF 50%.
able 1. Baseline Characteristics of Patients
Carvedilol
(n  25)
Control
(n  25) p Value
ge (yrs) 46.8  14 49.0  9.8 NS
emale (%) 88 84 NS
MI (kg/m2) 1.75  12.7 1.71  21.1 NS
aseline LVEF (%) 70.6  8.0 69.7  7.3 NS
LVDd (mm) 47.7  5.3 45.5  4.8 NS
LVSd (mm) 31.4  5.0 30.2  4.7 NS
ype of cancer, n (%)
Breast 18 (72) 16 (64) NS
Lymphoma 4 (16) 5 (20) NS
Other 3 (12) 4 (16) NS
T strategy, n (%)
CEF/CAF 17 (68) 16 (64) NS
CHOP/ABVD 4 (16) 4 (16) NS
Other 4 (16) 5 (20) NS
otal adriamycin dose
(mg/m2)
525.3 513.6 NS
otal epirubicin dose
(mg/m2)
787.9 770.4 NS
umber of cycles 6 6
ontrol echocardiography
time (months)
5.0  1.1 5.4  1.3 NS
 0.05 considered statistically significant. Data expressed as mean  SD or
ercentage.
ABVD  adriamycin, bleomycin, vinblastine, decarbazine; BMI  body mass
ndex; CEF/CAF  cyclophosphamide, adriamycin/epirubicin, fluorouracil;
HOP  cyclophosphamide, adriamycin, vincristin, prednisone; CT  chemother-
Abbreviations and Acronyms
ANT  anthracycline
CMP  cardiomyopathy
CT  chemotherapy
EF  ejection fraction
LV  left ventricle/ventricular
SERCA2  sarcoplasmic reticulum Ca2-ATPaseE
py; LVDd  left ventricular diastolic diameter; LVEF  left ventricular ejection
raction; LVSd  left ventricular systolic diameter; NS  not significant.iastolic functions were evaluated according to changes in
itral inflow parameters.
tatistical analysis. Data are expressed as mean values
SD or proportions. A paired t test was used to investigate
he time-dependent variables and Student t test to compare
groups. A p value0.05 was accepted as significant. SPSS
1.5 software (SPSS, Chicago, Illinois) was used for statis-
ical analysis.
ESULTS
he baseline characteristics are shown in Table 1. We
nrolled 25 patients each in the carvedilol and control groups.
t end of 6 months of follow-up, 1 patient in the carvedilol
roup and 4 in control had died. Mortality rates between the 2
roups were not significantly different (p  0.7).
All patients underwent control echocardiographic exam-
nation after 5.2  1.2 months. Control echocardiography
evealed an EF 50% in 1 subject in the carvedilol group
nd in 5 of the control subjects. The mean EF of the
arvedilol group was similar in basal and control echocar-
iographic examination, but the patients in the control
roup had significantly lower EF at the end of the follow-up
eriod compared with basal values (p 0.001) (Fig. 1). The
ndividual data are shown in Figure 2.
In addition to these findings, although there was no
ignificant change in both systolic and diastolic diameters of
V in the carvedilol group (systolic: 31.4 5.4 mm vs. 32.2
6.6 mm; p 0.7; diastolic: 47.6 5.6 mm vs. 47.4 3.7
m; p  0.8) both systolic and diastolic diameters were
ignificantly increased in the control group (systolic: 30.3 
.2 mm vs. 38.0  5.3 mm; p  0.0001; diastolic: 45.6 
.0 mm vs. 50.9  5.6 mm; p  0.008). A patient in the
arvedilol group who had low EF after CT and a patient
rom the control group who had decompensated heart
ailure and low EF were hospitalized. Another 3 patients
ith low EF were given medical therapy (not hospitalized).
Doppler study showed a significant decrease of E veloc-
ties in the carvedilol group; however, other parameters were
imilar (Table 2). In the contol group, both E velocities and
igure 1. Comparison of left ventricular ejection fraction (EF) at baseline
black bars) and after chemotherapy (white bars) in the 2 groups. Data
xpressed as mean values./A ratios were significantly reduced in control echocardi-
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/A ratio changes.
ISCUSSION
arlier animal studies have shown that prophylactic use of
arvedilol prevents ANT-induced CMP (11,12). The
resent study is the first clinical study related to use of
rophylactic carvedilol in ANT-induced CMP. We have
emonstrated that coadministration of carvedilol during CT
reserves the LV systolic functions. The mean EF after CT
n the carvedilol group was similar to baseline EF but
ignificantly decreased in the control group. Also, systolic
ysfunction occurred less in the carvedilol group.
Four patients died in the control group, and only 1
atient died in the carvedilol group. Mortality rates between
he 2 groups were not statistically different. A possible
eason for the inability to reach statistically significance
etween mortality rates may be the limited number of
atients in this study. Although not reaching statistically
ignificance, we suggest that the higher mortality rate in the
ontrol group may have clinical importance.
It has been demonstrated that ANT-induced CMP is
haracterized by minimal LV enlargement and global sys-
olic dysfunction (17). In line with that conclusion, our
atients with systolic dysfunction had mild or moderately
ncreased LV diameters, but in patients receiving carvedilol,
V diameters did not increase. Previous studies have shown
hat LV diastolic functions might also be impaired in
able 2. Results of Doppler Examination on Carvedilol Group
Baseline After CT p Value
eak E velocity (cm/s) 80.2  18.4 70.5  17.1 0.03*
eak A velocity (cm/s) 75.1  13.9 73.9  14.3 0.79
/A ratio 1.08  0.2 0.98  0.2 0.23
VRT (ms) 64.3  19.9 75.6  17.8 0.1
VCT (ms) 57.6  19.6 72.3  23.1 0.1
p  0.05 considered statistically significant. Data expressed as mean  SD.
Figure 2. Individual systolic function data at baseline and after chemothCT  chemotherapy; IVCT  isovolemic contraction time; IVRT  isovolumic
elaxation time. ratients receiving CT (18). Diastolic functions were affected
n our patients. Mitral E wave velocity and E/A ratio
ignificantly decreased in the control group, but the E/A
atio was similar before and after CT in the carvedilol
roup. These results indicate that carvedilol in patients
eceiving CT may protect diastolic function.
The reason for the cardioprotective effects of carvedilol in
NT-induced CMP is not fully known. However, cardio-
rotection may occur through the potent antioxidant activ-
ty of carvedilol. Both carvedilol and its metabolites were
hown to have antioxidant effects (19). It was reported that
ree oxygen radicals in failing heart were reduced by admin-
stration of carvedilol (20). When it is considered that
xidative stress is a major pathogenetic mechanism, antiox-
dant properties of carvedilol may be responsible for the
eneficial effects of the drug that occurred in our study.
However, other possible mechanisms may involve the
rotection of carvedilol. Sarcoplasmic reticulum Ca2-
TPase (SERCA2) may be another key factor in ANT-
nduced cardiotoxicity. Doxorubicin causes down-regulation
f SERCA2 messenger RNA in animals with cardiac
ysfunction (21). In addition, ANT has been noted to
timulate the release of Ca2 in cardiomyocytes (22).
arvedilol restores SERCA2 promoter activity in myocytes
nd it can block down-regulation of SERCA2 gene expres-
ion independent of its beta-blocking activity (23). These
ffects of carvedilol may be an underlying mechanism of its
eneficial effects on cardiac function. Treatment of carve-
ilol is also associated with inhibition of apoptotic signaling
(CT) in the 2 groups. *p  0.001; †p  0.3. EF  ejection fraction.
able 3. Results of Doppler Examination on Control Group
Baseline After CT p Value
eak E velocity (cm/s) 69.8  15.2 58.4  17.9 0.019*
eak A velocity (cm/s) 68.7  13.0 68.0  14.2 0.79
/A ratio 1.03  0.2 0.87  0.2 0.02*
VRT (ms) 72.7  16.1 72.7  2.0 0.9
VCT (ms) 73.3  18.7 78.8  18.3 0.5
p  0.05 considered statistically significant. Data expressed as mean  SD.
CT  chemotherapy; IVCT  isovolemic contraction time; IVRT  isovolemic
elaxation time.
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December 5, 2006:2258–62 Carvedilol on Anthracycline Cardiomyopathyathways (13). Because apoptosis plays a highly significant
ole in ANT-induced CMP (24), the antiapoptotic proper-
ies of carvedilol could be another important factor in
rotection from ANT-induced CMP.
According to our results, carvedilol, a beta-blocker, pre-
ented ANT-induced CMP. This result suggests that other
eta-blockers may have a similar protective effect. Mito-
hondrial dysfunction has a significant role in ANT cardio-
oxicity. Earlier studies have shown that carvedilol prevents
itochondrial dysfunction (12). However, an experimental
tudy showed that carvedilol was superior to propranolol in
revention of the mitochondrial dysfunction (25). Carve-
ilol prevented hydroxyl radical–induced cardiac contractile
ysfunction, but metoprolol did not (26). Similarly, despite
arvedilol-prevented ANT-induced apoptosis, atenolol did
ot have this effect (13). Because oxidative stress and
itochondrial dysfunction are likely the most important
actors in ANT-induced CMP, these data suggest that
arvedilol is superior to other beta-blockers for preventing
NT-induced CMP owing to its antioxidant and antiapop-
otic properties.
Various doses of carvedilol were used in earlier studies,
nd this is still a controversial subject. We used carvedilol at
2.5 mg once daily. This dose was lower than the dose of
revious studies (27). The recommended dose in the
OCHA (Multicenter Oral Carvedilol Heart Failure As-
essment) trial was 12.5 to 50 mg. Most of the previous
eart failure studies concerning carvedilol, because of pa-
ients’ tolerance, recommended an initial carvedilol dose of
.125 mg twice daily. However, in some studies, carvedilol
as used once daily, and it was demonstrated that even
ow-dose (6.25 mg) carvedilol has potential antioxidative
ffects (28). We considered these factors in determining the
arvedilol dose. Moreover, there were no diagnoses or
ymptoms of heart failure at baseline in our patients.
herefore, we used carvedilol at 12.5 mg once daily, because
e considered that the antioxidant properties of carvedilol
Figure 3. Individual change in mitral early/late diastolic flow (E/A) ratioay appear in low dose and that a single dose facilitatesatient compliance with therapy. However, further clinical
tudies are needed to find the most appropriate dose.
tudy limitations. The main limitation of our study is
nrollment of a limited number of patients. We found less
ortality in the carvedilol group, but the mortality differ-
nce between the 2 groups was not significant. The limited
umber of patients may be the reason for this result. Early
ardiac toxicity, which occurs during or soon after treatment
ith ANT, is mainly dependent on the cumulative ANT
ose (13). However, delayed CMP may occur after therapy
n some patients. We evaluated the protective effect of
arvedilol only on early cardiotoxic effects of CT and did not
valuate late-term effects of CT.
onclusions. Preventing ANT-induced CMP is an im-
ortant clinical problem. Prophylactic use of carvedilol in
hese patients may protect LV function. Although carvedilol
dministration seems to be related with low mortality,
urther large randomized clinical trials are needed.
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